The estimated Net Worth of Julianne Bruno is at least $459 Tisíc dollars as of 20 June 2024. Julianne Bruno owns over 7,000 units of CRISPR Therapeutics AG stock worth over $459,444 and over the last few years Julianne sold CRSP stock worth over $0.
Julianne has made over 1 trades of the CRISPR Therapeutics AG stock since 2024, according to the Form 4 filled with the SEC. Most recently Julianne exercised 7,000 units of CRSP stock worth $318,080 on 20 June 2024.
The largest trade Julianne's ever made was exercising 7,000 units of CRISPR Therapeutics AG stock on 20 June 2024 worth over $318,080. On average, Julianne trades about 3,500 units every 0 days since 2024. As of 20 June 2024 Julianne still owns at least 10,111 units of CRISPR Therapeutics AG stock.
You can see the complete history of Julianne Bruno stock trades at the bottom of the page.
Julianne's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON, MA, 02127.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani a Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: